The microbiome associated with oral Leukoplakia: A multi-omics mechanistic study
与口腔白斑相关的微生物组:一项多组学机制研究
基本信息
- 批准号:10870268
- 负责人:
- 金额:$ 41.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAlgorithmsAmericanAnimalsArtificial IntelligenceAutomobile DrivingBinding ProteinsBioinformaticsBiological MarkersCanadaCandidaCandida albicansCase/Control StudiesCell ProliferationCessation of lifeCoculture TechniquesComplementCoupledDNADataDetectionDevelopmentDiagnosticDiseaseDysplasiaEarly InterventionEnrollmentEpithelial CellsEpitheliumEventFoundationsFusobacteriumFusobacterium nucleatumFutureGene ExpressionGenesGenotypeGoalsHealthHealthcare SystemsHumanIn VitroInternationalInterventionIntraepithelial NeoplasiaInvadedKnowledgeLesionLongitudinal StudiesMalignant - descriptorMalignant NeoplasmsMarker DiscoveryMatrix MetalloproteinasesMediatingMesenchymalMetagenomicsMetalsOncogenicOralOral LeukoplakiaOral StagePathway interactionsPatient-Focused OutcomesPatientsPeptide HydrolasesPhasePhenotypePilot ProjectsPopulationPreventionProcessProductionPrognosisProliferatingPropertyResearchResolutionResourcesRoleSalivaSamplingSeveritiesShotgunsSwabTransforming Growth Factor betaUp-Regulationanalysis pipelinebioinformatics pipelinecarcinogenesiscarcinogenicitycohortcomparison groupcostcytokinedata integrationdiagnostic biomarkerdysbiosisearly detection biomarkersepithelial to mesenchymal transitionexperimental studyhigh riskhost-associated microbial communitieshost-microbe interactionsimprovedinsightinterestknock-downmalignant mouth neoplasmmetagenomic sequencingmetatranscriptomemicrobialmicrobial communitymicrobial compositionmicrobial signaturemicrobiomemicrobiome compositionmicroorganismmouth squamous cell carcinomamultiple omicsnoninvasive diagnosisnovelnovel diagnosticsoral carcinogenesisoral cavity epitheliumoral dysplasiaoral microbiomepremalignantprognosticprospectiverecruitresponsesaliva samplesecondary analysistranscriptometumor microenvironment
项目摘要
Project Summary
There is increasing interest in the role of the microbiome in the development and/or progression of various
cancers including oral squamous cell carcinoma (OSCC). Research has shown that OSCC is associated with a
distinct microbiome. However, OSCC in itself represents a late stage in a disease process in which the observed
microbial changes are as likely to be passenger or, at best, late driving events. To better understand the role of
the microbiome in OSCC and identify microbial biomarkers for early detection and prevention, it is crucial to
assess the microbiome in early stages of the disease, e.g. oral potentially malignant disorders (OPMDs). Oral
leukoplakia (OL; the focus of this study) is the most common OPMD. Little is known about the microbiome
associated with OPMDs, its role in their progression, or its potential as non-invasive diagnostic biomarker to
complement oral epithelial dysplasia grading, currently the best available indicator. Our long-term goal is to
identify diagnostic/prognostic microbial biomarkers of OPMDs and determine the effect of the microbiome on
oral carcinogenesis by conducting a large-scale, international consortium study in two phases: a case-control
study (this application) to comprehensively study the dysbiotic microbiome associated with OL/dysplasia in a
North American population; followed by a longitudinal study (future application) that will involve following up the
same and additional cohorts of OPMDs to identify/validate microbiome biomarkers of malignant transformation
(MT). Our hypothesis is that shifts in microbiome composition and function associated with OL represent early
driver events that correlate with the severity of dysplasia and contribute to the progression of oral cancer. In
addition, we also hypothesize that oncogenic strains of oral microorganisms could be driving these disorders.
To address these hypotheses, we propose 3 specific aims: 1) Characterize the composition of the multi-kingdom
microbiome associated with OL and the different grades of dysplasia; 2) Define both microbial and host
transcriptomes in OL and potential interactions between these two segments of the metatranscriptome. 3)
Assess in vitro the oncogenic properties of bacterial and fungal strains isolated from OL. The study will be
conducted by a team of international experts and will enroll 210 OL patients, 105 OSCC patients, and 420 healthy
control subjects (735 subjects in total) to be recruited in two study centers. One-thousand and five hundred saliva
and swab samples will be analyzed using shotgun metagenomic and metatranscriptome analysis. Furthermore,
36 bacterial/fungal strains previous isolated from OL patients with different grades of dysplasia will be screened
for their effect on proliferation, invasion, epithelial-mesenchymal transition and cytokine and matrix
metalloproteinases production by normal and dysplastic epithelial cells in vitro. The study will establish the role
of the microbiome in the early stages of oral carcinogenesis, and identify microbial biomarkers of OL and
dysplasia, which in a subsequent study can be validated as biomarkers of MT.
项目摘要
人们越来越关注微生物组在各种疾病的发展和/或进展中的作用。
癌症,包括口腔鳞状细胞癌(OSCC)。研究表明,口腔鳞状细胞癌与
独特的微生物组然而,OSCC本身代表了疾病过程的晚期阶段,其中观察到的
微生物的变化很可能是乘客或最好的情况下,晚驾驶事件。为了更好地理解
口腔鳞状细胞癌中的微生物组,并确定微生物生物标志物进行早期检测和预防,这是至关重要的,
评估疾病早期阶段的微生物组,例如口腔潜在恶性疾病(OPMD)。口服
白斑病(OL;本研究的重点)是最常见的OPMD。对微生物组知之甚少
与OPMD相关,其在其进展中的作用,或其作为非侵入性诊断生物标志物的潜力,
补充口腔上皮异型增生分级,目前最好的可用指标。我们的长期目标是
确定OPMD的诊断/预后微生物生物标志物,并确定微生物组对
口腔癌的发病机制进行了大规模的,国际财团研究分两个阶段:一个病例对照
研究(本申请)全面研究与OL/发育不良相关的生态失调微生物组
北美人群;随后是一项纵向研究(未来应用),将涉及随访
用于鉴定/验证恶性转化的微生物组生物标志物的相同和额外OPMD队列
(MT)。我们的假设是,与OL相关的微生物组组成和功能的变化代表了早期
与异型增生的严重程度相关的驱动事件,并有助于口腔癌的进展。在
此外,我们还假设口腔微生物的致癌菌株可能导致这些疾病。
为了解决这些假设,我们提出了3个具体目标:1)表征多王国的组成
与OL相关的微生物组和不同级别的发育不良; 2)定义微生物和宿主
OL中的转录组以及元转录组的这两个片段之间的潜在相互作用。第三章
评估从OL分离的细菌和真菌菌株的体外致癌特性。本研究将
由国际专家团队进行,将招募210名OL患者,105名OSCC患者和420名健康人。
在两个研究中心招募对照受试者(共735例受试者)。一千五百口水
并使用鸟枪宏基因组学和元转录组学分析来分析拭子样品。此外,委员会认为,
将筛选36株先前从具有不同程度异型增生的OL患者中分离的细菌/真菌菌株
对细胞增殖、侵袭、上皮-间质转化、细胞因子和基质的影响
体外正常和发育异常上皮细胞的金属蛋白酶产生。这项研究将确定
在口腔癌发生的早期阶段的微生物组,并确定OL和
发育异常,在随后的研究中可以验证为MT的生物标志物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nezar Al-Hebshi其他文献
Nezar Al-Hebshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nezar Al-Hebshi', 18)}}的其他基金
Microbiome-host interactions in oral squamous cell carcinoma: a meta-transcriptomic exploratory study
口腔鳞状细胞癌中微生物组与宿主的相互作用:一项宏转录组学探索性研究
- 批准号:
9809205 - 财政年份:2019
- 资助金额:
$ 41.43万 - 项目类别:
In vitro reproducible model of subgingival microbiome for high throughput screening for microbiome modulators
用于微生物组调节剂高通量筛选的龈下微生物组体外可重复模型
- 批准号:
9973103 - 财政年份:2019
- 资助金额:
$ 41.43万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 41.43万 - 项目类别:
Research Grant














{{item.name}}会员




